ASCO Annual Meeting

Healio.com brings you the highlights from the ASCO Annual Meeting. Refer back to this page often to read the latest news from ASCO, see perspectives and interviews with leading researchers and clinicians, and review archives of past meetings.

Meeting News

Radiation benefits patients with lung cancer who relapse after chemotherapy

August 11, 2017
CHICAGO – Thoracic radiation used in combination with chemotherapy may improve survival outcomes compared with chemotherapy alone in patients…
Meeting NewsVideo

VIDEO: Gefitinib may ‘change the paradigm’ to treat lung cancer

August 10, 2017
CHICAGO — Lecia V. Sequist, MD, MPH, the Mary B. Saltonstall Endowed Chair in Oncology at Massachusetts General Hospital and
Meeting News

Guest Commentary: Resistance to androgen-targeting agents highlights unmet need in prostate cancer

August 10, 2017
In this guest commentary, Leonard J. Appleman, MD, PhD, of the division of hematology/oncology at the University of Pittsburgh
Meeting News

Resuming treatment with cabazitaxel provides ‘option’ in advanced prostate cancer

August 8, 2017
CHICAGO – Retreatment with cabazitaxel demonstrated encouraging activity and acceptable toxicity when used in combination with a new hormonal…
Meeting News

Shorter duration of androgen deprivation therapy reduces side effects in prostate cancer

August 7, 2017
CHICAGO – Reducing the duration of androgen deprivation therapy from 36 to 18 months improved quality of life without affecting survival…
Meeting News

Palbociclib fails to reach response rate in lung cancer

August 6, 2017
CHICAGO — Palbociclib failed to reach a pre-specified response rate in patients with stage IV squamous cell lung cancer, according to results…
Meeting News

Ado-trastuzumab emtansine offers effective alternative as first-line therapy in breast cancer

August 3, 2017
CHICAGO — First-line therapy with ado-trastuzumab emtansine improved OS and reduced grade 3 and higher adverse events in patients with…
Meeting News

Durvalumab induces durable responses in urothelial cancer

August 2, 2017
CHICAGO — Durvalumab demonstrated an encouraging clinical response and a positive safety profile in patients with locally advanced or…
Meeting News

Cabozantinib appears safe, effective across age groups in renal cell carcinoma

August 1, 2017
CHICAGO — Age does not appear to impact the efficacy of cabozantinib for the treatment of advanced renal cell carcinoma, according to a…
Meeting NewsVideo

VIDEO: Pembrolizumab benefits patients with HER-2–negative breast cancer

July 31, 2017
CHICAGO – The addition of pembrolizumab to standard chemotherapy improved the pathologic complete response rate among women with…
Advertisement
Advertisement